196 related articles for article (PubMed ID: 2549205)
1. Phase I clinical investigation of amonafide.
Saez R; Craig JB; Kuhn JG; Weiss GR; Koeller J; Phillips J; Havlin K; Harman G; Hardy J; Melink TJ
J Clin Oncol; 1989 Sep; 7(9):1351-8. PubMed ID: 2549205
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer.
Berger MZ; Kris MG; Gralla RJ; Marks LD; Potanovich LM; Dimaggio JJ; Heelan RT
Am J Clin Oncol; 1991 Apr; 14(2):124-6. PubMed ID: 1851387
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical investigation of benzisoquinolinedione.
Legha SS; Ring S; Raber M; Felder TB; Newman RA; Krakoff IH
Cancer Treat Rep; 1987 Dec; 71(12):1165-9. PubMed ID: 3690526
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group study.
Marshall ME; Blumenstein B; Crawford ED; Thompson IM; Craig JB; Eisenberger M; Ahmann F
Am J Clin Oncol; 1994 Dec; 17(6):514-5. PubMed ID: 7977172
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of amonafide in advanced pancreatic adenocarcinoma.
Linke K; Pazdur R; Abbruzzese JL; Ajani JA; Winn R; Bradof JE; Daugherty K; Levin B
Invest New Drugs; 1991 Nov; 9(4):353-6. PubMed ID: 1804812
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group.
Gesme DH; Jett JR; Schreffler DD; Su JQ; Mailliard JA; Foley JF; Krook JE; Maksymiuk AW; Hatfield AK; Ebbert LP
Cancer; 1993 May; 71(9):2723-6. PubMed ID: 8385564
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of amonafide in advanced breast cancer.
Scheithauer W; Dittrich C; Kornek G; Haider K; Linkesch W; Gisslinger H; Depisch D
Breast Cancer Res Treat; 1991 Dec; 20(1):63-7. PubMed ID: 1813070
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of amonafide in advanced and recurrent sarcoma patients.
Perez RP; Nash SL; Ozols RF; Comis RL; O'Dwyer PJ
Invest New Drugs; 1992 Jul; 10(2):99-101. PubMed ID: 1500272
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of amonafide (nafidamide, NSC 308847) in advanced colorectal cancer.
O'Dwyer PJ; Paul AR; Hudes GR; Walczak J; Ozols RF; Comis RL
Invest New Drugs; 1991 Feb; 9(1):65-7. PubMed ID: 2026485
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of amonafide dosing based on acetylator phenotype.
Ratain MJ; Mick R; Berezin F; Janisch L; Schilsky RL; Vogelzang NJ; Lane LB
Cancer Res; 1993 May; 53(10 Suppl):2304-8. PubMed ID: 8485716
[TBL] [Abstract][Full Text] [Related]
13. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of amonafide in advanced colorectal cancer: a SouthWest Oncology Group study.
Brown TD; Goodman PJ; Fleming T; Macdonald JS; Craig JB; Einstein AB
Anticancer Drugs; 1993 Feb; 4(1):49-50. PubMed ID: 8457714
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of amonafide in patients with endometrial cancer: a Gynecologic Oncology Group Study.
Asbury R; Blessing JA; Reid GC; McGuire WP
Am J Clin Oncol; 1998 Aug; 21(4):406-7. PubMed ID: 9708643
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of Amonafide in dogs.
Lu K; McLean MA; Vestal ML; Newman RA
Cancer Chemother Pharmacol; 1988; 21(2):134-8. PubMed ID: 3349561
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
[TBL] [Abstract][Full Text] [Related]
18. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of amonafide in advanced sarcoma: a Southwest Oncology Group study.
Buys SS; Metch B; Balcerzak SP; Neefe JR; Stuckey WJ
Cancer Invest; 1994; 12(4):399-402. PubMed ID: 8032960
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer.
Evans WK; Eisenhauer EA; Cormier Y; Ayoub J; Wierzbicki R; Laberge F; Shepherd FA
J Clin Oncol; 1990 Mar; 8(3):390-5. PubMed ID: 2155309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]